Breaking News

365mc, Raziel Therapeutics Partner to Jointly Advance RZL-012 in South Korea

RZL-012 is an injectable treatment for focal fat reduction that is currently progressing toward Phase 3 trials.

Author Image

By: Charlie Sternberg

Associate Editor

L to R: Dr. Patricia Walker, CMO Raziel Therapeutics; Dr. Nam-Chul Kim, Founder and CEO of 365mc; Dr. Philippe Schaison, Chairman of the Board Raziel therapeutics.

365mc, a South Korean medical institution specializing in fat reduction treatments, and Raziel Therapeutics, a global clinical-stage biopharmaceutical company, have announced a strategic collaboration to jointly advance the clinical and commercial development of RZL-012 in South Korea. RZL-012 is an injectable treatment for focal fat reduction that is currently progressing toward Phase 3 trials. 365mc is renowned for its patient-centered and comprehensive approach to fat management, offering ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters